Colorectal Surgery Division, Department of Surgery, St Paul's Hospital, Vancouver, BC, Canada.
Department of Public Health, University of Saskatchewan, Saskatoon, SK, Canada.
Colorectal Dis. 2021 Sep;23(9):2407-2415. doi: 10.1111/codi.15771. Epub 2021 Jul 10.
Perianal sepsis in Crohn's disease (CD) fistulas is managed with antibiotics and surgical drainage; a noncutting seton is used for an identified transsphincteric fistula tract. The optimal management following seton placement for initial control of perianal sepsis remains to be determined. Our main aim was to assess the success rates of curative surgery, seton removal or long-term indwelling seton in patients with and without CD.
This was a retrospective cohort of consecutive patients with a perianal fistula treated with a noncutting seton between 2010 and 2019, including 83 CD patients and 94 patients without CD. Initial control of symptomatic perianal infection with a seton and subsequent healing and reintervention rates were compared between the three postseton management strategies.
A total of 177 patients, 61% male and 83.1% with complex fistulas, were followed for a median of 23 months (interquartile range 11-40 months). Immunomodulatory treatment was used in 90.4% of CD patients after seton placement. Good initial control of perianal infection was achieved with a seton in CD and non-CD patients, at 92.9% and 96.7%, respectively (p = 0.11). Overall fistula healing or control for CD and non-CD patients was, respectively, 64% and 86% (p = 0.1) after curative surgery, 49% and 71% after seton removal (p = 0.21) and 58% and 50% with long-term seton placement (p = 0.72). Overall reintervention for recurrence was 83% in CD versus 53.1% in non-CD patients during the follow-up period (p = 0.002).
Definitive surgery was possible in only a minority of CD patients. Long-term seton management was an effective option in patients with CD with acceptable improvement and recurrence rates.
克罗恩病(CD)肛瘘的肛周脓肿采用抗生素和外科引流治疗;对于明确的经括约肌瘘管,使用非切割式挂线。目前,对于经挂线治疗后肛周脓肿的初始控制,哪种后续管理方案最佳尚不清楚。我们的主要目的是评估在有和没有 CD 的患者中,采用根治性手术、挂线移除或长期留置挂线治疗的成功率。
这是一项回顾性队列研究,纳入了 2010 年至 2019 年间接受非切割式挂线治疗的肛周瘘患者,包括 83 例 CD 患者和 94 例非 CD 患者。比较了三种挂线治疗后管理策略对有症状的肛周感染初始控制、后续愈合和再干预的效果。
共纳入 177 例患者,61%为男性,83.1%为复杂瘘,中位随访时间为 23 个月(四分位距 11-40 个月)。在放置挂线后,90.4%的 CD 患者接受了免疫调节治疗。在 CD 和非 CD 患者中,挂线治疗均能很好地控制初始肛周感染,分别为 92.9%和 96.7%(p=0.11)。在 CD 和非 CD 患者中,根治性手术分别有 64%和 86%(p=0.1)、挂线移除分别有 49%和 71%(p=0.21)、长期留置挂线分别有 58%和 50%(p=0.72)达到瘘管愈合或控制。在随访期间,CD 患者的总体再干预率为 83%,而非 CD 患者为 53.1%(p=0.002)。
在 CD 患者中,仅有少数患者可行根治性手术。对于 CD 患者,长期挂线管理是一种有效的选择,其改善和复发率均可以接受。